Updated: Eli Lilly expects FDA decision on Alzheimer’s drug by end of year as it unveils full PhIII data

Lei Lei Wu

News Reporter

Eli Lilly said Monday morning that it has submitted an application for its experimental Alzheimer’s drug donanemab to the FDA, and expects a decision by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Eli Lilly expects FDA decision on Alzheimer’s drug by end of year as it unveils full PhIII data

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

Breaking down silos with a new quantitative approach to drug development

Up­dat­ed: Eli Lil­ly ex­pects FDA de­ci­sion on Alzheimer’s drug by end of year as it un­veils full PhI­II da­ta

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Eli Lilly expects FDA decision on Alzheimer’s drug by end of year as it unveils full PhIII data